AAAlexander J. Allen

Alexander J. Allen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander J. Allen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hypofractionated and Stereotactic Body Proton Radiotherapy for a High-Risk Lung Cancer Cohort: A Multi-Institutional Experience from the Proton Collaborative Group Prospective Registry

    by Alexander Allen, Ii Charles B. Simone, Kai Sun, David F. Alicia, Ajay Banskota, Gopal K. Bajaj, John H. Chang, James R. Gray, Ryan S. Grover, Christian Hyde, et al.

    INTRODUCTION: Lung cancer is commonly treated with stereotactic body radiotherapy (SBRT) and hypofractionated RT (HFRT). Delivery of these ablative techniques via proton beam therapy (PBT) may yield dosimetric and clinical advantages. We evaluated safety and efficacy of HF and SBRT PBT to treat lung tumors, including high-risk subgroups.METHODS: We analyzed adult patients from a prospective, multi-institutional registry treated for lung tumors with PBT ≤15 fractions. Regimens of 4-5 fractions at ≥10Gy/fraction (≥48Gy total) or 8-15 fractions at ≥3.5Gy/fraction (≥52.5Gy total) were included. Local control (LC) was estimated by cumulative incidence, with Fine-Gray models for subgroup comparisons.RESULTS: 104 patients with 110 tumors (83.6% non-small cell lung cancer) were included: 32.7% ≥4cm, 41.8% ultracentral, and 30% re-irradiated. Most common regimens were 60Gy/15 fractions (40%) and 50Gy/5 fractions (17.2%); 71.8% received intensity-modulated PBT. 1-, 2-, and 5-year LC rates were 87.3%, 81.8%, and 80.0%, respectively, with no difference by tumor size, ultracentral location, or re-irradiation. Univariate analysis showed internal gross tumor volume receiving 95% of dose was associated with improved local recurrence (p=0.007). Most common toxicities were cough (40%) and dyspnea (34.5%) with no Grade ≥3 toxicities. Re-irradiated patients had greater overall cough (p=0.014), ultracentral patients had higher Grade 2 cough (p=0.046), and patients with tumors ≥4cm had higher chest wall pain (p=0.012) and pneumonitis (p=0.042).CONCLUSIONS: In the largest prospectively enrolled report of SBRT or HFRT via intensity-modulated PBT to treat lung tumors, robust LC and favorable toxicity rates were achieved, even among ≥ 4 cm, re-irradiated, and ultracentral tumors.

  • Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer

    by Alexander J. Allen, Bansi Savla, Claudia Datnow-Martinez, William Mendes, Sophia C. Kamran, Stefan Ambs, Zachery Keepers, Caitlin Eggleston, Kaysee Baker, Jason K. Molitoris, et al.

    PURPOSE: As oncologic precision medicine develops, there is concern that tumor genomic profiling among Black patients and other underrepresented demographics will lag and amplify health disparities. We evaluate whether a precision medicine navigator (PMN), a clinical navigator specialized in obtaining tumor genomic testing for patients, is associated with increased genomic testing rates and whether this is the case among Black patients and other disadvantaged groups. METHODS: We retrospectively reviewed prostate cancer consults within one health care system from November 2, 2021, to January 2, 2023. We compared the proportion of patients who received genomic testing in the 7 months before the PMN start (pre-PMN) to the 7 months afterward (post-PMN). Binary logistic regression was used to calculate the odds of receiving testing. RESULTS: The sample included 693 patients, 311 pre-PMN and 382 post-PMN. Racial distribution and clinical stage were well-balanced between the pre- and post-PMN groups. From pre- to post-PMN, the proportion of patients receiving testing increased from 18% to 70% ( P = .0002). Significant increases in testing post-PMN occurred among Black patients, lower median income patients, patients with Medicare/Medicaid, and community hospital patients. However, utilization post-PMN was significantly higher in non-Black compared with Black patients, 75.4% and 58.5%, respectively ( P = .0006). CONCLUSION: For patients with prostate cancer, the presence of a PMN is associated with increased rates of genomic testing overall, including among Black patients and other groups that experience health inequities. Utilization post-PMN was significantly lower in Black patients compared with non-Black patients. More research is needed into why Black patients show lower rates of genomic testing.